REPORT ID 233

China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Research Report Forecast 2017-2021

Publish Date
25-Dec-17
Pages
123
Format
Electronic (PDF)

The China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Non-alcoholic Fatty Liver Disease (NAFLD) Drug industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Non-alcoholic Fatty Liver Disease (NAFLD) Drug market study provides comprehensive data which enhances the understanding, scope and application of this report.
This report provides comprehensive analysis of
Key market segments and sub-segments
Evolving market trends and dynamics
Changing supply and demand scenarios
Quantifying market opportunities through market sizing and market forecasting
Tracking current trends/opportunities/challenges
Competitive insights
Opportunity mapping in terms of technological breakthroughs

The Major players reported in the market include:
Conatus Pharmaceuticals
Daewoong Pharmaceutical
Galmed International
Kyorin Pharmaceutical
Metabolic Solutions Development
Novartis AG
Phenex Pharmaceuticals
Raptor Pharmaceuticals
TCM Biotech International
...

China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market: Product Segment Analysis
Type 1
Type 2
Type 3 

China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market: Application Segment Analysis
Application 1
Application 2
Application 3 

Reasons for Buying this Report
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth 
It provides a six-year forecast assessed on the basis of how the market is predicted to grow 
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments  
			   
China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Research Report Forecast 2017-2021

Chapter 1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Overview
1.1 Product Overview and Scope of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
1.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Segmentation by Type
1.2.1 China Production Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Type 1n 2016
1.2.1 Type 1
1.2.2 Type 2
1.2.3 Type 3
1.3 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Segmentation by Application
1.3.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Market Share by Application in 2016
1.3.2 Application 1 
1.3.3 Application 2
1.3.4 Application 3
1.4 China Market Size Sales (Value) and Revenue (Volume) of Non-alcoholic Fatty Liver Disease (NAFLD) Drug (2012-2021) 

Chapter 2 China Economic Impact on Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industry
2.1 China Macroeconomic Environment Analysis
2.1.1 China Macroeconomic Analysis
2.1.2 China Macroeconomic Environment Development Trend
2.2 Effects to Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industry

Chapter 3 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Competition by Manufacturers
3.1 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production and Share by Manufacturers (2015 and 2016)
3.2 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Share by Manufacturers (2015 and 2016)
3.3 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Average Price by Manufacturers (2015 and 2016)
3.4 Manufacturers Non-alcoholic Fatty Liver Disease (NAFLD) Drug Manufacturing Base Distribution, Production Area and Product Type
3.5 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Competitive Situation and Trends
3.5.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Concentration Rate
3.5.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share of Top 3 and Top 5 Manufacturers
3.5.3 Mergers & Acquisitions, Expansion

Chapter 4 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Capacity, Production, Revenue, Consumption, Export and Import (2012-2017)
4.1 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Capacity, Production and Growth (2012-2017)
4.2 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth (2012-2017)
4.3 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Consumption, Export and Import (2012-2017)

Chapter 5 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue (Value), Price Trend by Type
5.1 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production and Market Share by Type (2012-2017)
5.2 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by Type (2012-2017)
5.3 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price by Type (2012-2017)
5.4 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production Growth by Type (2012-2017)

Chapter 6 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Analysis by Application
6.1 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption and Market Share by Application (2012-2017)
6.2 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Growth Rate by Application (2012-2017)
6.3 Market Drivers and Opportunities
6.3.1 Potential Applications
6.3.2 Emerging Markets/Countries

Chapter 7 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Manufacturers Analysis
7.1 Conatus Pharmaceuticals
7.1.1 Company Basic Information, Manufacturing Base and Competitors
7.1.2 Product Type, Application and Specification
7.1.3 Production, Revenue, Price and Gross Margin (2012-2017)
7.1.4 Business Overview
7.2 Daewoong Pharmaceutical
7.2.1 Company Basic Information, Manufacturing Base and Competitors
7.2.2 Product Type, Application and Specification
7.2.3 Production, Revenue, Price and Gross Margin (2012-2017)
7.2.4 Business Overview
7.3 Galmed International
7.3.1 Company Basic Information, Manufacturing Base and Competitors
7.3.2 Product Type, Application and Specification
7.3.3 Production, Revenue, Price and Gross Margin (2012-2017)
7.3.4 Business Overview
7.4 Kyorin Pharmaceutical
7.4.1 Company Basic Information, Manufacturing Base and Competitors
7.4.2 Product Type, Application and Specification
7.4.3 Production, Revenue, Price and Gross Margin (2012-2017)
7.4.4 Business Overview
7.5 Metabolic Solutions Development
7.5.1 Company Basic Information, Manufacturing Base and Competitors
7.5.2 Product Type, Application and Specification
7.5.3 Production, Revenue, Price and Gross Margin (2012-2017)
7.5.4 Business Overview
7.6 Novartis AG
7.6.1 Company Basic Information, Manufacturing Base and Competitors
7.6.2 Product Type, Application and Specification
7.6.3 Production, Revenue, Price and Gross Margin (2012-2017)
7.6.4 Business Overview
7.7 Phenex Pharmaceuticals
7.7.1 Company Basic Information, Manufacturing Base and Competitors
7.7.2 Product Type, Application and Specification
7.7.3 Production, Revenue, Price and Gross Margin (2012-2017)
7.7.4 Business Overview
7.8 Raptor Pharmaceuticals
7.8.1 Company Basic Information, Manufacturing Base and Competitors
7.8.2 Product Type, Application and Specification
7.8.3 Production, Revenue, Price and Gross Margin (2012-2017)
7.8.4 Business Overview
7.9 TCM Biotech International
7.9.1 Company Basic Information, Manufacturing Base and Competitors
7.9.2 Product Type, Application and Specification
7.9.3 Production, Revenue, Price and Gross Margin (2012-2017)
7.9.4 Business Overview
?

Chapter 8 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Manufacturing Cost Analysis
8.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers
9.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Non-alcoholic Fatty Liver Disease (NAFLD) Drug Major Manufacturers in 2015
9.4 Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List

Chapter 11 Market Effect Factors Analysis
11.1 Technology Progress/Risk
11.1.1 Substitutes Threat
11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change

Chapter 12 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Forecast (2017-2021)
12.1 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue Forecast (2017-2021)
12.2 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Consumption Forecast by Regions (2017-2021)
12.3 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production Forecast by Type (2017-2021)
12.4 China Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast by Application (2017-2021)
12.5 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price Forecast (2017-2021)

Chapter 13 Appendix